Cariprazine on Psychosis: Beyond Schizophrenia - A Case Series

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2022 Jul 12

PMID 35818373

Authors

Miguel Bajouco

David Mota

Affiliations

Soon will be listed here.

Abstract

Cariprazine is an atypical antipsychotic that has D2 and D3 partial agonism properties in addition to the usual 5-HT2A receptor antagonist action of second-generation antipsychotics. It has a distinctly higher affinity for D3 receptors, which is 10-fold higher than for D2 receptors. Cariprazine is also a 5-HT1A partial agonist, with a potential antidepressant effect. Cariprazine has been approved for treatment of both positive and negative symptoms of schizophrenia and for treatment of bipolar disorder. It could potentially be used in depression as an add-on treatment. There are few data reporting effectiveness of cariprazine in the broader spectrum of psychosis. In this paper, the authors report three cases where cariprazine was used in the treatment of psychotic conditions other than schizophrenia, namely a first episode psychosis, a case of delusional disorder, and a case of a patient with borderline personality disorder and psychotic symptoms. The authors suggest that cariprazine may be effective in the treatment of psychosis in a broader sense and should be considered a first-line treatment option.

Citing Articles

Cariprazine in the management of emotionally unstable personality disorder in female patients: a case series.

Pappa S, Caldwell-Dunn E, Kalniunas A, Kamal M Front Psychiatry. 2024; 15:1421698.

PMID: 39132320 PMC: 11310661. DOI: 10.3389/fpsyt.2024.1421698.

A Case Report of Treatment With Cariprazine in a Recurrent Psychosis Presumably Induced by Methamphetamine.

Moran R, Hastings C, Della-Pietra U, Singh C, Jacome M Cureus. 2023; 15(10):e47135.

PMID: 38021522 PMC: 10650934. DOI: 10.7759/cureus.47135.

Cariprazine for negative symptoms in early psychosis: a pilot study with a 6-month follow-up.

Pappa S, Kalniunas A, Maret J Front Psychiatry. 2023; 14:1183912.

PMID: 37426095 PMC: 10323827. DOI: 10.3389/fpsyt.2023.1183912.

Seventy Years of Treating Delusional Disorder with Antipsychotics: A Historical Perspective.

Gonzalez-Rodriguez A, Monreal J, Natividad M, Seeman M Biomedicines. 2022; 10(12).

PMID: 36552037 PMC: 9775530. DOI: 10.3390/biomedicines10123281.

References

Birchwood M, Todd P, Jackson C . Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl. 1998; 172(33):53-9. View

Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S . Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull. 2014; 41(4):892-9. PMC: 4466178. DOI: 10.1093/schbul/sbu170. View

Slotema C, Daalman K, Blom J, Diederen K, Hoek H, Sommer I . Auditory verbal hallucinations in patients with borderline personality disorder are similar to those in schizophrenia. Psychol Med. 2012; 42(9):1873-8. DOI: 10.1017/S0033291712000165. View

Kane J, Zukin S, Wang Y, Lu K, Ruth A, Nagy K . Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial. J Clin Psychopharmacol. 2015; 35(4):367-73. DOI: 10.1097/JCP.0000000000000346. View

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F . Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896):951-62. DOI: 10.1016/S0140-6736(13)60733-3. View

Kay S, Fiszbein A, Opler L . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2):261-76. DOI: 10.1093/schbul/13.2.261. View

Corponi F, Serretti A, Montgomery S, Fabbri C . Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol. 2017; 32(6):309-318. DOI: 10.1097/YIC.0000000000000189. View

Garnock-Jones K . Cariprazine: A Review in Schizophrenia. CNS Drugs. 2017; 31(6):513-525. DOI: 10.1007/s40263-017-0442-z. View

Hansenne M, Pitchot W, Pinto E, Reggers J, Scantamburlo G, Fuchs S . 5-HT1A dysfunction in borderline personality disorder. Psychol Med. 2002; 32(5):935-41. DOI: 10.1017/s0033291702005445. View

10.

Orsolini L, de Berardis D, Volpe U . Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opin Drug Saf. 2020; 19(8):981-998. DOI: 10.1080/14740338.2020.1795126. View

11.

Wesolowska A, Partyka A, Jastrzebska-Wiesek M, Kolaczkowski M . The preclinical discovery and development of cariprazine for the treatment of schizophrenia. Expert Opin Drug Discov. 2018; 13(8):779-790. DOI: 10.1080/17460441.2018.1471057. View

12.

Dieci M, Trama A, Mansi G . Resolution of Citalopram Sexual Adverse Effects With Low Dose of Cariprazine: A Case Report. Clin Neuropharmacol. 2020; 43(5):164-165. DOI: 10.1097/WNF.0000000000000409. View

13.

McGorry P, Edwards J, Mihalopoulos C, Harrigan S, Jackson H . EPPIC: an evolving system of early detection and optimal management. Schizophr Bull. 1996; 22(2):305-26. DOI: 10.1093/schbul/22.2.305. View

14.

Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S . Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019; 29(9):971-985. DOI: 10.1016/j.euroneuro.2019.06.008. View

15.

Durgam S, Cutler A, Lu K, Migliore R, Ruth A, Laszlovszky I . Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015; 76(12):e1574-82. DOI: 10.4088/JCP.15m09997. View

16.

Friedel R . Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology. 2004; 29(6):1029-39. DOI: 10.1038/sj.npp.1300424. View

17.

Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F . Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand. 2000; 102(3):203-10. DOI: 10.1034/j.1600-0447.2000.102003203.x. View

18.

Iannuzzi G, Patel A, Stewart J . Aripiprazole and Delusional Disorder. J Psychiatr Pract. 2019; 25(2):132-134. DOI: 10.1097/PRA.0000000000000368. View

19.

Yatham L, Kennedy S, Parikh S, Schaffer A, Bond D, Frey B . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018; 20(2):97-170. PMC: 5947163. DOI: 10.1111/bdi.12609. View

20.

Freudenmann R, Schonfeldt-Lecuona C, Lepping P . Primary delusional parasitosis treated with olanzapine. Int Psychogeriatr. 2007; 19(6):1161-8. DOI: 10.1017/S1041610207004814. View